Ono Pharmaceutical Co LtdOno Pharmaceutical Co Ltd - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

If you are employed by Ono Pharmaceutical Co Ltd and you would like to use your ESG rating, please get in touch. The article includes a questions and answers section about Ono Pharmaceutical Co Ltd. Alternative corporations in the rating industry group for Ono Pharmaceutical Co Ltd are shown below.

Ono Pharmaceutical Co Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 8.0; made up of an environmental score of 8.0, social score of 8.0 and governance score of 8.0.

SDG Transparency Score for Ono Pharmaceutical Co Ltd 
Low
0 - 3
Medium
4 - 6

8.0

High Impact
7 - 10
Last Score Update: 2023-07-01
What drives the score for Ono Pharmaceutical Co Ltd 
8.0

Environmental

8.0

Social

8.0

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Novartis AG
9.2
High
2Daiichi Sankyo Co Ltd
8.9
High
36Repligen Corp
8.1
High
36Zealand Pharma A/S
8.1
High
55Ono Pharmaceutical Co Ltd
8.0
High
55Abbott India Ltd
8.0
High
55Amrutanjan Health Care Ltd
8.0
High
.........
2749Xynomic Pharmaceuticals Holdings Inc
0.0
Low
2749Zyden Gentec Ltd
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does Ono Pharmaceutical Co Ltd have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does Ono Pharmaceutical Co Ltd disclose current and historical energy intensity?

LockedSign up for free to unlock

Does Ono Pharmaceutical Co Ltd report the average age of the workforce?

LockedSign up for free to unlock

Does Ono Pharmaceutical Co Ltd reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does Ono Pharmaceutical Co Ltd disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does Ono Pharmaceutical Co Ltd disclose cybersecurity risks?

LockedSign up for free to unlock

Does Ono Pharmaceutical Co Ltd offer flexible work?

LockedSign up for free to unlock

Does Ono Pharmaceutical Co Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does Ono Pharmaceutical Co Ltd disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does Ono Pharmaceutical Co Ltd conduct supply chain audits?

LockedSign up for free to unlock

Does Ono Pharmaceutical Co Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does Ono Pharmaceutical Co Ltd conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does Ono Pharmaceutical Co Ltd disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does Ono Pharmaceutical Co Ltd disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does Ono Pharmaceutical Co Ltd disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does Ono Pharmaceutical Co Ltd disclose water use targets?

LockedSign up for free to unlock

Does Ono Pharmaceutical Co Ltd have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did Ono Pharmaceutical Co Ltd have a product recall in the last two years?

LockedSign up for free to unlock

Does Ono Pharmaceutical Co Ltd disclose incidents of discrimination?

LockedSign up for free to unlock

Does Ono Pharmaceutical Co Ltd allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has Ono Pharmaceutical Co Ltd issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does Ono Pharmaceutical Co Ltd disclose parental leave metrics?

LockedSign up for free to unlock

Does Ono Pharmaceutical Co Ltd disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does Ono Pharmaceutical Co Ltd disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does Ono Pharmaceutical Co Ltd disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does Ono Pharmaceutical Co Ltd support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does Ono Pharmaceutical Co Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does Ono Pharmaceutical Co Ltd reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is Ono Pharmaceutical Co Ltd involved in embryonic stem cell research?

LockedSign up for free to unlock

Does Ono Pharmaceutical Co Ltd disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does Ono Pharmaceutical Co Ltd disclose its waste policy?

LockedSign up for free to unlock

Does Ono Pharmaceutical Co Ltd report according to TCFD requirements?

LockedSign up for free to unlock

Does Ono Pharmaceutical Co Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does Ono Pharmaceutical Co Ltd disclose energy use targets?

LockedSign up for free to unlock

Does Ono Pharmaceutical Co Ltd disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does Ono Pharmaceutical Co Ltd have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for Ono Pharmaceutical Co Ltd
These potential risks are based on the size, segment and geographies of the company.

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors. The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis. In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.

Sorry!

Failed to process!